Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02451384
Other study ID # B2015-010
Secondary ID
Status Recruiting
Phase N/A
First received May 14, 2015
Last updated June 28, 2015
Start date June 2015
Est. completion date December 2016

Study information

Verified date June 2015
Source Shanghai Zhongshan Hospital
Contact n/a
Is FDA regulated No
Health authority China: Ethics Committee
Study type Interventional

Clinical Trial Summary

Acccording circulating tumor cells to compare the differences of different methods(routine method、no-touch principle method、laparoscopy method) to remove the ductal adenocarcinoma of pancreatic body and tail.


Recruitment information / eligibility

Status Recruiting
Enrollment 45
Est. completion date December 2016
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- Ductal adenocarcinoma of pancreatic body and tail

- Tumor can be removed

- No other tumors and without liver metastases

- Age from 18 to 80 years old

Exclusion Criteria:

- Neoplasms with other sites of the pancreas

- With other tumors of any other sites

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Procedure:
routine surgery
To observe if the surgeries can influence the countings of circulating tumor cells of the patients.
no-touch surgery

laparoscopic surgery


Locations

Country Name City State
China Genaral surgery department of Zhongshan Hospital, Fudan University Shanghai Shanghai
China Zhongshan Hospital Affiliated to Fudan University Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai Zhongshan Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the changes of CTCs countings between the pre and post-operation in each arm Within 1 week after the surgeries are completed in any arm Yes
Primary the changes of CTCs countings between the pre and post-operation among the arms Within 2 weeks after the surgeies are all completed Yes
See also
  Status Clinical Trial Phase
Recruiting NCT03500068 - Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study. N/A
Not yet recruiting NCT05489458 - Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
Recruiting NCT02310230 - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy N/A
Completed NCT01478685 - A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT03513705 - Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1) N/A
Completed NCT01808638 - Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) Phase 1/Phase 2
Withdrawn NCT00226746 - Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer Phase 2
Not yet recruiting NCT03432624 - Detection of MicroRNA-25 in the Diagnosis of Pancreatic Cancer N/A
Recruiting NCT02529579 - Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer Phase 1/Phase 2
Not yet recruiting NCT06447662 - A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. Phase 1
Recruiting NCT02817308 - Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas N/A
Completed NCT00471146 - Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. Phase 3
Recruiting NCT05461430 - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Terminated NCT01413451 - Amatuximab for High Mesothelin Cancers Early Phase 1
Recruiting NCT03403101 - The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer Phase 2
Recruiting NCT02928081 - Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma N/A
Completed NCT05723978 - Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
Completed NCT02150746 - Circulating Tumor Cells in Operative Blood N/A
Completed NCT04146441 - Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma Phase 2
Not yet recruiting NCT05621824 - A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS